Company

XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M

Fineline Cube
By
Fineline Cube
4 Min Read
XtalPi Achieves First Profitability – AI Drug Discovery Revenue Surges 418% to RMB 538M, Global Sales Hit RMB 803M
Summarize with AI

QuantumPharm Inc. (HKG: 2228), operating as XtalPi Inc., reported 2025 financial results, achieving first annual profitability with net profit of RMB 135 million (USD 19.6 million). The company became the first profitable Hong Kong-listed company in the AI for Science (AI4S) sector, with global sales skyrocketing 201.2% YoY to RMB 803 million (USD 116 million). The drug discovery solutions business drove exceptional growth, surging 418.9% to RMB 538 million fueled by antibody business expansion and milestone achievements across partner pipelines.

Contents
- Advertisement -

Financial Highlights

Metric2025 ResultYoY ChangeSector Significance
Global SalesRMB 803 million (USD 116M)+201.2%Hypergrowth validates AI drug discovery commercial model
Net ProfitRMB 135 million (USD 19.6M)First profitable yearFirst HK-listed AI4S profitability – sector milestone
Drug Discovery SolutionsRMB 538 million (USD 78M)+418.9%Core engine of growth; antibody business + partner milestones
AI Models Deployed200+ industry modelsCumulativeFull-chain coverage: target discovery → preclinical screening

Business Segment Performance

Segment2025 RevenueGrowth DriverStrategic Impact
Drug Discovery SolutionsRMB 538MAntibody business rapid expansion; partner/incubated company milestone achievementsProfitability engine – high-margin SaaS + milestone economics
Materials Science (Battery, Semiconductor)RMB 265M (implied)AI-driven R&D for energy and electronics sectorsDiversification beyond pharma; industrial AI applications
TotalRMB 803MAI platform scalability across verticalsValidation of AI for Science (AI4S) business model

AI Platform Progress

Capability2025 AchievementCompetitive Position
AI Model Portfolio200+ models covering entire drug discovery chainMost comprehensive AI platform in China biotech
Strategic CollaborationsSystematic deepening with global pharma and biotech partnersRevenue visibility through multi-year partnerships
Core Model IterationContinuous algorithm improvement in molecular generation, ADMET prediction, protein structureTechnical moat vs. emerging AI competitors
Novel Drug PlatformsExpansion into antibody, ADC, PROTAC, siRNA modalitiesPlatform breadth supports diverse partner pipelines

Strategic Context: AI4S Sector Leadership

FactorImplication
Profitability MilestoneFirst HK-listed AI4S profitability validates unit economics of AI drug discovery; reduces skepticism about AI platform sustainability
Antibody Business Surge418% growth reflects biologics industry shift toward AI-enabled discovery; XtalPi captures trend with generative antibody design
Partner Milestone EconomicsRevenue model shifts from pure SaaS fees to success-based milestones – aligns incentives and improves margins
Global Expansion“Global sales” designation suggests ex-China revenue contribution growing; positions for U.S./EU partnerships
Sector ValuationProfitability supports premium valuation vs. pre-revenue AI biotech peers; potential index inclusion (Hang Seng Tech)
  • 2026 Catalysts: Additional profitability quarters; major pharma partnership announcements; AI model regulatory validation (FDA/EMA engagement on AI-generated INDs)
  • Competitive Landscape: Positions against Schrödinger (SDGR), Recursion (RXRX), Insilico Medicine; XtalPi’s first profitability + China market depth provides differentiation

Forward‑Looking Statements
This brief contains forward‑looking statements regarding sustained profitability, partner pipeline progression, and AI model regulatory acceptance. Actual results may differ due to partner milestone timing, competitive AI platform development, and macroeconomic factors affecting biotech R&D spending.-Fineline Info & Tech

TAGGED:
Share This Article
Previous Article Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year Everest Medicines Revenue Surges 142% to RMB 1.7B – Nefecon Becomes First Non-Oncology Drug to Hit RMB 1B in First NRDL Year
Next Article Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

You May also Like

CompanyLegal / IP

J&J Loses US Court Case Over Asbestos in Cosmetic Products; Ordered to Pay $260 Million

Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors
CompanyDrug

Huadong Medicine Receives NMPA Approval for HDM2012 Clinical Trials in Advanced Solid Tumors

CompanyDrug

Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients

CompanyDeals

InflaRx and Staidson Amend Deal to Advance Vilobelimab Regulatory Filing in China

Show More